Geode Capital Management’s Genocea Biosciences, Inc. GNCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-291,733
| Closed | -$364K | – | 5101 |
|
|
2022
Q1 | $364K | Buy |
291,733
+84,853
| +41% | +$92.4K | ﹤0.01% | 4104 |
|
|
2021
Q4 | $239K | Buy |
206,880
+20,938
| +11% | +$31.2K | ﹤0.01% | 4398 |
|
|
2021
Q3 | $357K | Buy |
185,942
+6,228
| +3% | +$12.2K | ﹤0.01% | 4182 |
|
|
2021
Q2 | $420K | Buy |
179,714
+6,307
| +4% | +$15.2K | ﹤0.01% | 4021 |
|
|
2021
Q1 | $469K | Hold |
173,407
| – | – | ﹤0.01% | 3835 |
|
|
2020
Q4 | $419K | Hold |
173,407
| – | – | ﹤0.01% | 3642 |
|
|
2020
Q3 | $397K | Buy |
173,407
+4,406
| +3% | +$11.6K | ﹤0.01% | 3494 |
|
|
2020
Q2 | $388K | Buy |
169,001
+18,036
| +12% | +$41.5K | ﹤0.01% | 3461 |
|
|
2020
Q1 | $259K | Hold |
150,965
| – | – | ﹤0.01% | 3473 |
|
|
2019
Q4 | $312K | Buy |
150,965
+1,882
| +1% | +$4.46K | ﹤0.01% | 3663 |
|
|
2019
Q3 | $432K | Buy |
149,083
+119,318
| +401% | +$407K | ﹤0.01% | 3518 |
|
|
2019
Q2 | $116K | Buy |
29,765
+2,597
| +10% | +$13.5K | ﹤0.01% | 3930 |
|
|
2019
Q1 | $128K | Hold |
27,168
| – | – | ﹤0.01% | 3843 |
|
|
2018
Q4 | $62K | Hold |
27,168
| – | – | ﹤0.01% | 3949 |
|
|
2018
Q3 | $169K | Sell |
27,168
-192
| -0.7% | -$1.01K | ﹤0.01% | 3800 |
|
|
2018
Q2 | $187K | Sell |
27,360
-17,747
| -39% | -$133K | ﹤0.01% | 3738 |
|
|
2018
Q1 | $378K | Buy |
45,107
+22,092
| +96% | +$183K | ﹤0.01% | 3490 |
|
|
2017
Q4 | $213K | Sell |
23,015
-1,673
| -7% | -$16.8K | ﹤0.01% | 3658 |
|
|
2017
Q3 | $288K | Buy |
24,688
+520
| +2% | +$19.7K | ﹤0.01% | 3540 |
|
|
2017
Q2 | $1.01M | Buy |
24,168
+5,622
| +30% | +$271K | ﹤0.01% | 3098 |
|
|
2017
Q1 | $903K | Buy |
18,546
+838
| +5% | +$32.7K | ﹤0.01% | 3064 |
|
|
2016
Q4 | $583K | Buy |
17,708
+36
| +0.2% | +$1.19K | ﹤0.01% | 3215 |
|
|
2016
Q3 | $723K | Buy |
17,672
+2,753
| +18% | +$108K | ﹤0.01% | 3102 |
|
|
2016
Q2 | $489K | Sell |
14,919
-2,205
| -13% | -$80.8K | ﹤0.01% | 3235 |
|
|
2016
Q1 | $1.06K | Buy |
17,124
+218
| +1% | +$6.92K | ﹤0.01% | 2850 |
|
|
2015
Q4 | $712K | Buy |
16,906
+193
| +1% | +$9.2K | ﹤0.01% | 3081 |
|
|
2015
Q3 | $915K | Buy |
16,713
+5,355
| +47% | +$531K | ﹤0.01% | 2921 |
|
|
2015
Q2 | $1.25M | Buy |
11,358
+1,403
| +14% | +$130K | ﹤0.01% | 2788 |
|
|
2015
Q1 | $944K | Buy |
9,955
+4,144
| +71% | +$292K | ﹤0.01% | 2908 |
|
|
2014
Q4 | $325K | Buy |
5,811
+19
| +0.3% | +$1.3K | ﹤0.01% | 3383 |
|
|
2014
Q3 | $419K | Buy |
5,792
+1,583
| +38% | +$173K | ﹤0.01% | 3244 |
|
|
2014
Q2 | $631K | Buy |
4,209
+26
| +0.6% | +$3.94K | ﹤0.01% | 3048 |
|
|
2014
Q1 | $608K | Buy |
+4,183
| New | +$513K | ﹤0.01% | 3061 |
|
Other funds holding GNCA
Geode Capital Management's GNCA Position: Q2 2022 in Review
Geode Capital Management sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 291,733 shares — an estimated $364K sold.
Geode Capital Management first reported a position in GNCA in Q1 2014 and held it in 33 quarters. The position peaked at $1.25M in Q2 2015. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.
- Geode Capital Management reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
- Geode Capital Management sold 291,733 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $364K.
- Geode Capital Management first reported a position in Genocea Biosciences, Inc. in Q1 2014 and held it in 33 quarters.
- Geode Capital Management's Genocea Biosciences, Inc. position peaked at $1.25M in Q2 2015.
- 5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.
Based on Geode Capital Management's 13F filing for Q2 2022, filed 12 Aug 2022.